Minerva Surgical Inc., a commercial-stage medical technology company, focuses on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
IPO Year: 2021
Exchange: NASDAQ
Website: minervasurgical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/9/2022 | $17.00 → $12.00 | Overweight | Piper Sandler |
| 12/3/2021 | $17.00 → $12.00 | Outperform | SVB Leerink |
| 11/16/2021 | $17.00 | Outperform | SVB Leerink |
| 11/16/2021 | $15.00 | Buy | UBS |
| 11/16/2021 | $14.00 | Overweight | JP Morgan |
| 11/16/2021 | $17.00 | Overweight | Piper Sandler |
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro
SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an
SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously
SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously
SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00
UBS initiated coverage of Minerva Surgical with a rating of Buy and set a new price target of $15.00
JP Morgan initiated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $14.00
Piper Sandler initiated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $17.00
15-12G - MINERVA SURGICAL INC (0001452965) (Filer)
25 - MINERVA SURGICAL INC (0001452965) (Filer)
S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
10-Q - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
8-K - MINERVA SURGICAL INC (0001452965) (Filer)
SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o
SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co
SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a woman's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported fourth quarter and full-year financial results for the period ended December 31, 2022. Fourth Quarter and Recent Business Highlights: Reported revenue of $13.8 million in the fourth quarter of 2022, compared with revenue of $13.6 million in the fourth quarter of 2021 and $12.6 million in the third quarter of 2022Symphion revenue of $12.1 million for full-year 2022 increased 13% from 2021Appointed Todd Usen as Chief Executive Officer at the start o
SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pers
SANTA CLARA, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has closed on the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed Partners (Accelmed), with participation by New Enterprise Associates, at an offering price of $0.2046 per share. Accelmed is now the controlling stockholder of Minerva Surgical. Gross proceeds of the private placement are approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical. Piper Sandler acted
SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time. A live audio webcast and replay of the presentation may be accessed through the "Recent Events" section of Minerva's website at http://ir.minervasurgical.com. About Minerva Surgical, Inc. Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally
SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o
SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co
SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a woman's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported fourth quarter and full-year financial results for the period ended December 31, 2022. Fourth Quarter and Recent Business Highlights: Reported revenue of $13.8 million in the fourth quarter of 2022, compared with revenue of $13.6 million in the fourth quarter of 2021 and $12.6 million in the third quarter of 2022Symphion revenue of $12.1 million for full-year 2022 increased 13% from 2021Appointed Todd Usen as Chief Executive Officer at the start o
SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pers
SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022. Third Quarter and Recent Business Highlights: Reported revenue of $12.6 million in the third quarter of 2022, compared with revenue of $12.5 million in the third quarter of 2021 and $13.0 million in the second quarter of 2022Symphion revenue of $3.0 million increased 10% from the third quarter of 2021Website visitors for AUBandMe.com, an educational website which was launched in the fourth qu
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call. It will now report its third quarter 2022 financial results on Monday, November 14, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will r
SANTA CLARA, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN tha
SANTA CLARA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported second quarter financial results for the period ended June 30, 2022. Second Quarter and Recent Business Highlights: Reported revenue of $13.0 million in the second quarter of 2022, compared with revenue of $10.9 million in the first quarter of 2022 and $14.1 million in the second quarter of 2021Symphion revenue of $3.3 million increased 19% from the first quarter of 2022, and 20% from the second quarter of 2021Minerva endometrial ablation revenue of $5.8 million w
SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that c
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13G/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13G - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13G/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13G/A - MINERVA SURGICAL INC (0001452965) (Subject)